StockData
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. (DSGN) stock

DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$9.84−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $615.80MP/E –Yield –

Design Therapeutics cash

Cash and short-term investments held at the end of each period.

Design Therapeutics's cash was $207.40M at Jun 30, 2026. For fiscal 2025 it was $219.80M, down 10.5% from the year before. The highest annual figure on record is $384.10M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$219.80M-10.5%
FY2024Dec 31, 2024$245.50M-12.9%
FY2023Dec 31, 2023$281.80M-14.7%
FY2022Dec 31, 2022$330.40M-14.0%
FY2021Dec 31, 2021$384.10M+964.3%
FY2020Dec 31, 2020$36.09M+46771.4%
FY2019Dec 31, 2019$77.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$207.40M-4.1%
Q1 FY2026Mar 31, 2026$222.80M-3.0%
Q4 FY2025Dec 31, 2025$219.80M-10.5%
Q3 FY2025Sep 30, 2025$206.00M-18.9%
Q2 FY2025Jun 30, 2025$216.30M-17.1%
Q1 FY2025Mar 31, 2025$229.70M-15.1%
Q4 FY2024Dec 31, 2024$245.50M-12.9%
Q3 FY2024Sep 30, 2024$254.10M-12.7%
Q2 FY2024Jun 30, 2024$261.00M-13.9%
Q1 FY2024Mar 31, 2024$270.70M-14.2%
Q4 FY2023Dec 31, 2023$281.80M-14.7%
Q3 FY2023Sep 30, 2023$290.90M-15.5%
Q2 FY2023Jun 30, 2023$303.10M-15.7%
Q1 FY2023Mar 31, 2023$315.40M-15.0%
Q4 FY2022Dec 31, 2022$330.40M-14.0%
Q3 FY2022Sep 30, 2022$344.20M-12.6%
Q2 FY2022Jun 30, 2022$359.40M-10.8%
Q1 FY2022Mar 31, 2022$371.20M-9.8%
Q4 FY2021Dec 31, 2021$384.10M+964.3%
Q3 FY2021Sep 30, 2021$393.72M+12112.1%
Q2 FY2021Jun 30, 2021$402.84M+21146.6%
Q1 FY2021Mar 31, 2021$411.34M+15123.5%
Q4 FY2020Dec 31, 2020$36.09M+46771.4%
Q3 FY2020Sep 30, 2020$3.22M–
Q2 FY2020Jun 30, 2020$1.90M–
Q1 FY2020Mar 31, 2020$2.70M–
Q4 FY2019Dec 31, 2019$77.00K–

More Design Therapeutics figures

See a number that looks wrong?